The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2-advanced breast cancer patients: A study of the Dutch SONABRE Registry

M. Meegdes, S.M.E. Geurts, F.L.G. Erdkamp, M.W. Dercksen, B.E.P.J. Vriens, K.N.A. Aaldering, M.J.A.E. Pepels, L.M.H. Winkel, N.J.A. Teeuwen, M. Boer, V.C.G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)124-131
Number of pages8
JournalInternational Journal of Cancer
Volume150
Issue number1
Early online date14 Sep 2021
DOIs
Publication statusPublished - 1 Jan 2022

Keywords

  • 6 inhibitors
  • CDK4
  • CHEMOTHERAPY
  • ENDOCRINE THERAPY
  • WOMEN
  • breast cancer
  • implementation
  • metastatic disease
  • real-world
  • SURVIVAL
  • PALBOCICLIB
  • PLUS FULVESTRANT

Cite this